A Randomized, Placebo-Controlled, Double-Blind Study of Escalating Single Doses of ITI-214 in Healthy Volunteers to Determine Central Nervous System Engagement, Safety and Tolerability

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of Escalating Single Doses of ITI-214 in Healthy Volunteers to Determine Central Nervous System Engagement, Safety and Tolerability

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs ITI 214 (Primary)
  • Indications Cognition disorders; Parkinson's disease
  • Focus Pharmacodynamics
  • Sponsors Intra-Cellular Therapies
  • Most Recent Events

    • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
    • 09 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top